High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
Top Cited Papers
Open Access
- 1 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (3), ofaa102
- https://doi.org/10.1093/ofid/ofaa102
Abstract
The outbreak of Coronavirus Disease 2019 (COVID-19) has spread rapidly in China. Till now, no definite effective treatment has been identified. We reported on three patients of severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.This publication has 16 references indexed in Scilit:
- Wave-CAIPI susceptibility-weighted imaging achieves diagnostic performance comparable to conventional susceptibility-weighted imaging in half the scan timeEuropean Radiology, 2020
- IVIG-mediated effector functions in autoimmune and inflammatory diseasesInternational Immunology, 2017
- Intravenous Immunoglobulin in the Treatment of Primary Immunodeficiency DiseasesPediatric Annals, 2017
- Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus InfectionAnnals of Internal Medicine, 2014
- Contrasting Mechanisms of Interferon‐α Inhibition by Intravenous Immunoglobulin After Induction by Immune Complexes Versus Toll‐like Receptor AgonistsArthritis & Rheumatism, 2013
- Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED]Neurology, 2012
- Advances in the understanding of the mechanism of action of IVIgZeitschrift für Neurologie, 2008
- Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the LiteratureClinical Infectious Diseases, 2008
- Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS PatientsEmerging Infectious Diseases, 2004
- Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w.British Journal of Haematology, 1999